Resources for students such as educational tools covering a variety of managed care topics and information on professional opportunities (internships, APPEs, fellowships and residencies) related to managed care pharmacy.
In this video, Christina, an artist, educator, and self-described "accidental advocate," shares her experience living with a desmoid tumor, a rare, locally invasive soft tissue tumor that forms in the body's connective tissue and is also known as aggressive fibromatosis or desmoid-type fibromatosis. She describes the uncertainty of her initial diagnosis, the multiple treatments that did not work, and finding a therapy that has helped keep her tumor stable.
As psychedelic-assisted therapies move closer to potential use in treating treatment-resistant depression (TRD), health plans, pharmacy benefit managers, and other managed care stakeholders are beginning to evaluate how these therapies could fit within existing coverage, reimbursement, and care delivery models. A new Journal of Managed Care + Specialty Pharmacy (JMCP) supplement from AMCP Market Insights provides a roadmap for many of the questions payers may face as innovative therapies enter the depression treatment landscape.
AMCP’s comments focus on provisions in the Proposed Rule that affect prescription drug payment and access to clinically appropriate therapies. AMCP has an interest in ensuring that Medicare payment and coverage policies promote transparency, control prices, preserve beneficiary access, and avoid fragmented incentives across care settings and benefit designs. AMCP encourages CMS to provide clear methodological explanations and monitor effects on beneficiary access and provider behavior.
On Aug. 28, AMCP responded to Senate HELP Chairman Bill Cassidy's 340B reform proposal.
AMCP supports efforts to make prescription medications more affordable for Medicare beneficiaries. At the same time, implementation of the Medicare Drug Price Negotiation Program (Negotiation Program) should preserve the evidence-based formulary management, utilization management, market competition, and clinical decision-making processes fundamental to managed care pharmacy.
The No Surprises Act Enforcement Act would increase insurer penalties up to $10,000 per surprise billing violation.
On June 16, Senate Finance Committee Democrats released an RFI on proposals to lower the cost of prescription drugs. On Aug. 17, AMCP submitted comments in response.
On June 5, the New York State Assembly passed S.5939C/A.5882C, commonly referred to as the Patient Access to Pharmacy Act (PAPA), sending the pharmacy benefit manager (PBM) reimbursement legislation to Governor Kathy Hochul for consideration. The Senate previously passed the measure on May 28.
On August 11, 2026, the Centers for Medicare and Medicaid Services issues a final rule titled, “Prohibition on Federal Medicaid and Children’s Health Insurance Program Funding for Sex-Rejecting Procedures Furnished to Children” (Final Rule).
The Final Rule prohibits payments to State Medicaid plans for “sex-rejecting procedures” for children under 18 or to a separate Children’s Health Insurance Program (CHIP) for children under 19. Among the definitions included in the Final Rule are:
